Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Clinical trial NCT05669664 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05669664
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Salivary Gland Carcinoma Metastatic Salivary Gland Carcinoma Recurrent Salivary Gland Carcinoma Unresectable Salivary Gland Carcinoma

Start date: 2023-07-20
Primary completion: 2026-11-30
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.